Griffin A J, Gibson T, Huston G
Br J Rheumatol. 1983 May;22(2):82-8. doi: 10.1093/rheumatology/22.2.82.
Forty-one patients were given sodium aurothiomalate either in the conventional dose of 50 mg weekly for five months or in a small dose of 10 mg weekly for the same period. Monthly maintenance injections of 50 mg and 20 mg, respectively, were continued for a further seven months. A high incidence of toxicity and the subsequent withdrawal of 15 patients from the study prevented any analysis of results beyond five months. Statistically significant clinical improvements occurred with both treatment regimes. Although there were no significant differences between the clinical measurements of the treatment groups at any stage, a significant reduction of ESR and serum IgM occurred only with the higher dose. Side-effects were more frequent and occurred earlier with conventional treatment. However, severe toxicity, demanding withdrawal from the study, was slightly more common in the low-dose group. Thus, at least in the short term, conventional- and low-dose regimes appeared equally effective. A small dose did not lesson the hazards of toxicity.
41名患者接受了硫代苹果酸金钠治疗，其中一组按常规剂量每周50毫克给药，持续五个月；另一组按小剂量每周10毫克给药，为期相同。之后分别继续每月注射50毫克和20毫克进行维持治疗，持续七个月。由于高毒性发生率以及随后15名患者退出研究，导致无法对五个月后的结果进行任何分析。两种治疗方案均出现了具有统计学意义的临床改善。尽管在任何阶段治疗组的临床测量结果之间没有显著差异，但仅高剂量组的血沉率（ESR）和血清免疫球蛋白M（IgM）出现了显著降低。常规治疗的副作用更频繁且出现得更早。然而，因严重毒性而要求退出研究的情况在低剂量组中略为常见。因此，至少在短期内，常规剂量和低剂量方案似乎同样有效。小剂量并未减轻毒性危害。
